U.S. Over the Counter (OTC) Drugs Market (By Product Type: Vitamin and Dietary Supplements, Cough and Cold Products, Analgesics, Gastrointestinal Products, Sleep Aids, Otic Products, Wart Removers, Mouth Care Products, Ophthalmic Products, Botanicals, Antacids, Smoking Cessation Products, Feminine Care, Others; By Dosage Form; By Route of Administration; By Distribution Channel) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Over the Counter (OTC) Drugs Market 

5.1. COVID-19 Landscape: U.S. Over the Counter (OTC) Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Over the Counter (OTC) Drugs Market, By Product Type

8.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Product Type, 2024-2033

8.1.1. Vitamin and Dietary Supplements

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Cough & Cold Products

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Analgesics

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Gastrointestinal Products

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Sleep Aids

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Otic Products

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Wart Removers

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Mouth Care Products

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Ophthalmic Products

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

8.1.10. Botanicals

8.1.10.1. Market Revenue and Volume Forecast (2021-2033)

8.1.11. Antacids

8.1.11.1. Market Revenue and Volume Forecast (2021-2033)

8.1.12. Smoking Cessation Products

8.1.12.1. Market Revenue and Volume Forecast (2021-2033)

8.1.13. Feminine Care

8.1.13.1. Market Revenue and Volume Forecast (2021-2033)

8.1.14. Others

8.1.14.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. U.S. Over the Counter (OTC) Drugs Market, By Dosage Form

9.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Dosage Form, 2024-2033

9.1.1. Tablets

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Hard Capsules

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Powders

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Ointments

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Soft Capsules

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Liquids

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Others

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. U.S. Over the Counter (OTC) Drugs Market, By Route of Administration 

10.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Parenteral

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Topical

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. U.S. Over the Counter (OTC) Drugs Market, By Distribution Channel 

11.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Distribution Channel, 2024-2033

11.1.1. Drug Stores & Retail Pharmacies

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Hospital Pharmacies

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. U.S. Over the Counter (OTC) Drugs Market and Trend Forecast

12.1. U.S.

12.1.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Dosage Form (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Bayer AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Takeda Pharmaceutical Company Ltd.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Johnson & Johnson Services Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Sanofi S.A.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Novartis AG

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Boehringer Ingelheim International GmbH

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. GlaxoSmithKline PLC

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Mylan

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. UPM Pharmaceuticals

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample